A C N Freitas1, D F Pacheco1,2, M F M Machado3, A K Carmona3, I D G Duarte2, M E de Lima1. 1. Departamento de Bioquímica e Imunologia, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil. 2. Departamento de Farmacologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil. 3. Departamento de Biofísica, Universidade Federal de São Paulo, São Paulo, SP, Brazil.
Abstract
BACKGROUND AND PURPOSE: The synthetic peptide PnPP-19 has been studied as a new drug candidate to treat erectile dysfunction. However, PnTx2-6, the spider toxin from which the peptide was designed, induces hyperalgesia. Therefore, we intended to investigate the role of PnPP-19 in the nociceptive pathway. EXPERIMENTAL APPROACH: Nociceptive thresholds were measured by paw pressure test. PnPP-19 was administered intraplantarly alone or with selective cannabinoid or opioid receptor antagonists. The hydrolysis of PnPP-19 by neutral endopeptidase (NEP) (EC 3.4.24.11), an enzyme that cleaves enkephalin, was monitored by HPLC and the cleavage sites were deduced by LC-MS. Inhibition by PnPP-19 and Leu-enkephalin of NEP enzyme activity was determined spectrofluorimetrically. KEY RESULTS: PnPP-19 (5, 10 and 20 μg per paw) induced peripheral antinociception in rats. Specific antagonists of μ opioid receptors (clocinnamox), δ opioid receptors (naltrindole) and CB1 receptors (AM251) partly inhibited the antinociceptive effect of PnPP-19. Inhibition of fatty acid amide hydrolase by MAFP or of anandamide uptake by VDM11 enhanced PnPP-19-induced antinociception. NEP cleaved PnPP-19 only after a long incubation, and Ki values of 35.6 ± 1.4 and 14.6 ± 0.44 μmol·L(-1) were determined for PnPP-19 and Leu-enkephalin respectively as inhibitors of NEP activity. CONCLUSIONS AND IMPLICATIONS: Antinociception induced by PnPP-19 appears to involve the inhibition of NEP and activation of CB1, μ and δ opioid receptors. Our data provide a greater understanding of the antinociceptive effects of PnPP-19. This peptide could be useful as a new antinociceptive drug candidate.
BACKGROUND AND PURPOSE: The synthetic peptide PnPP-19 has been studied as a new drug candidate to treat erectile dysfunction. However, PnTx2-6, the spider toxin from which the peptide was designed, induces hyperalgesia. Therefore, we intended to investigate the role of PnPP-19 in the nociceptive pathway. EXPERIMENTAL APPROACH: Nociceptive thresholds were measured by paw pressure test. PnPP-19 was administered intraplantarly alone or with selective cannabinoid or opioid receptor antagonists. The hydrolysis of PnPP-19 by neutral endopeptidase (NEP) (EC 3.4.24.11), an enzyme that cleaves enkephalin, was monitored by HPLC and the cleavage sites were deduced by LC-MS. Inhibition by PnPP-19 and Leu-enkephalin of NEP enzyme activity was determined spectrofluorimetrically. KEY RESULTS: PnPP-19 (5, 10 and 20 μg per paw) induced peripheral antinociception in rats. Specific antagonists of μ opioid receptors (clocinnamox), δ opioid receptors (naltrindole) and CB1 receptors (AM251) partly inhibited the antinociceptive effect of PnPP-19. Inhibition of fatty acid amide hydrolase by MAFP or of anandamide uptake by VDM11 enhanced PnPP-19-induced antinociception. NEP cleaved PnPP-19 only after a long incubation, and Ki values of 35.6 ± 1.4 and 14.6 ± 0.44 μmol·L(-1) were determined for PnPP-19 and Leu-enkephalin respectively as inhibitors of NEP activity. CONCLUSIONS AND IMPLICATIONS: Antinociception induced by PnPP-19 appears to involve the inhibition of NEP and activation of CB1, μ and δ opioid receptors. Our data provide a greater understanding of the antinociceptive effects of PnPP-19. This peptide could be useful as a new antinociceptive drug candidate.
Authors: S G de Figueiredo; M E de Lima; M Nascimento Cordeiro; C R Diniz; D Patten; R F Halliwell; J Gilroy; M Richardson Journal: Toxicon Date: 2001 Feb-Mar Impact factor: 3.033
Authors: Mohab M Ibrahim; Frank Porreca; Josephine Lai; Phillip J Albrecht; Frank L Rice; Alla Khodorova; Gudarz Davar; Alexandros Makriyannis; Todd W Vanderah; Heriberto P Mata; T Philip Malan Journal: Proc Natl Acad Sci U S A Date: 2005-02-10 Impact factor: 11.205
Authors: M Herkenham; A B Lynn; M D Little; M R Johnson; L S Melvin; B R de Costa; K C Rice Journal: Proc Natl Acad Sci U S A Date: 1990-03 Impact factor: 11.205
Authors: A C N Freitas; D F Pacheco; M F M Machado; A K Carmona; I D G Duarte; M E de Lima Journal: Br J Pharmacol Date: 2016-03-10 Impact factor: 8.739
Authors: Daniela da Fonseca Pacheco; Ana Cristina Nogueira Freitas; Adriano Monteiro C Pimenta; Igor Dimitri Gama Duarte; Maria Elena de Lima Journal: J Venom Anim Toxins Incl Trop Dis Date: 2016-12-21
Authors: Renata Cristina Mendes Ferreira; Ana Flávia Almeida-Santos; Igor Dimitri Gama Duarte; Daniele C Aguiar; Fabricio A Moreira; Thiago Roberto Lima Romero Journal: Biomed Res Int Date: 2017-07-03 Impact factor: 3.411
Authors: Carolina Nunes da Silva; Kenia Pedrosa Nunes; Lays Fernanda Nunes Dourado; Thayllon Oliveira Vieira; Xavier Maia Mariano; Armando da Silva Cunha Junior; Maria Elena de Lima Journal: Front Mol Biosci Date: 2022-04-11
Authors: Bruna Luiza Emerich; Renata C M Ferreira; Marta N Cordeiro; Márcia Helena Borges; Adriano M C Pimenta; Suely G Figueiredo; Igor Dimitri G Duarte; Maria Elena de Lima Journal: Toxins (Basel) Date: 2016-04-12 Impact factor: 4.546
Authors: Ana C N Freitas; Steve Peigneur; Flávio H P Macedo; José E Menezes-Filho; Paul Millns; Liciane F Medeiros; Maria A Arruda; Jader Cruz; Nicholas D Holliday; Jan Tytgat; Gareth Hathway; Maria E de Lima Journal: Toxins (Basel) Date: 2018-01-15 Impact factor: 4.546